Long-Term Commitment, Investment Needed To Implement WHO Snakebite Strategy

The Lancet: Snakebite — emerging from the shadows of neglect
Editorial Board

“…The burden of snakebite death and disability is equal to that of prostate or cervical cancer, and is greater than any other neglected tropical disease. Yet investment into snakebite has been just £30 million between 2008 and 2017, with limited research, stagnating development of treatments, and declining access to antivenoms in many countries. … With its triad of high mortality, marked disability, and substantial psychological morbidity, snakebite warrants major investment in research. … After decades of relative neglect, snakebite is now firmly on the global health agenda. With a strategy and substantial funding now in place, the stage is set. Will all actors play their parts? Testing and then implementing WHO’s strategy requires long-term commitment by governments of countries with a high burden of snakebite envenoming, in addition to further investment by donors. Only then will snakebite victims, who are often the poorest of the poor, have a better chance of survival” (6/1).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.